Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

National Framework Agreement for Adalimumab Injection 1 April 2023

NHS England

This public procurement record has 2 releases in its history.

Award

24 Mar 2023 at 11:45

Award Notice
Tender

26 Oct 2022 at 15:03

Tender Notice
Summary of the contracting process

The National Framework Agreement for Adalimumab Injection commencing on 1 April 2023 is a completed procurement project by NHS England. The agreement covers multiple regions including South of England, Midlands and East, London, and North of England. It includes options for extensions up to 24 months, with various contract periods for each lot. The procurement method used was an open procedure, with award criteria based on price. The main procurement category is goods within the pharmaceutical products industry.

This tender offers significant business opportunities for pharmaceutical companies looking to supply Adalimumab Injection to NHS regions in England. The procurement process involves active supplier involvement, as evidenced by multiple awards made to companies like Amgen Ltd, Sandoz Ltd, Biogen, Abbvie Ltd, Fresenius Kabi Limited, and Celltrion Healthcare United Kingdom Limited. Businesses interested in this opportunity should consider registering their interest on the NHS eTendering portal and complying with the submission requirements before the bid validity period ends on 26th February 2023.

How relevant is this notice?

Notice Information

Notice Title

National Framework Agreement for Adalimumab Injection 1 April 2023

Notice Description

Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023<br/> <br/>Offer reference number: CM/PHR/22/5660<br/> <br/>CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months<br/>CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Lot Information

CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab

Lot 4 - CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab

Lot 3 - CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to the London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab

Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab

Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-037c6c
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/008624-2023
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£478,880,000 £100M-£1B
Lots Value
£478,880,000 £100M-£1B
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
24 Mar 20233 years ago
Submission Deadline
28 Nov 2022Expired
Future Notice Date
Not specified
Award Date
14 Mar 20233 years ago
Contract Period
1 Apr 2023 - 31 Aug 2024 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LEEDS
Postcode
LS2 7UE
Postcode Area
Leeds
Country
England
Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE42 Leeds
Delivery Location
Not specified
Local Authority
Leeds
Electoral Ward
Little London & Woodhouse
Westminster Constituency
Leeds Central and Headingley

Supplier Information

Number of Suppliers
6
Supplier Names

Abbvie Ltd

Amgen Ltd

Biogen

Celltrion Healthcare United Kingdom Limited

Fresenius Kabi Limited

Sandoz Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...